USANA Health Sciences, Inc. to Post Q2 2024 Earnings of $0.68 Per Share, DA Davidson Forecasts (NYSE:USNA)

USANA Health Sciences, Inc. (NYSE:USNA) – Analysts at DA Davidson issued their Q2 2024 EPS estimates for shares of USANA Health Sciences in a research note issued on Tuesday, May 7th. DA Davidson analyst L. Weiser expects that the company will post earnings per share of $0.68 for the quarter. DA Davidson has a “Neutral” rating and a $46.00 price objective on the stock. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.75 per share.

Separately, StockNews.com upgraded USANA Health Sciences from a “buy” rating to a “strong-buy” rating in a research report on Friday, January 12th.

USANA Health Sciences Stock Up 2.9 %

Shares of USNA opened at $46.32 on Wednesday. The business’s 50-day moving average price is $46.38 and its 200-day moving average price is $48.04. USANA Health Sciences has a twelve month low of $41.45 and a twelve month high of $69.60. The stock has a market cap of $889.34 million, a PE ratio of 14.43, a P/E/G ratio of 1.38 and a beta of 0.94.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.52 by $0.35. USANA Health Sciences had a net margin of 6.88% and a return on equity of 12.80%. The company had revenue of $221.08 million for the quarter, compared to analysts’ expectations of $206.70 million.

Insider Transactions at USANA Health Sciences

In related news, insider Robert A. Sinnott sold 3,945 shares of USANA Health Sciences stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $46.55, for a total transaction of $183,639.75. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, insider Robert A. Sinnott sold 3,945 shares of the business’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $46.55, for a total value of $183,639.75. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider David Mulham Mulham sold 4,311 shares of the company’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $47.76, for a total transaction of $205,893.36. Following the sale, the insider now owns 7,825 shares in the company, valued at $373,722. The disclosure for this sale can be found here. Insiders have sold 34,286 shares of company stock valued at $1,634,010 over the last quarter. 0.33% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On USANA Health Sciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. State Board of Administration of Florida Retirement System lifted its position in shares of USANA Health Sciences by 22.7% during the first quarter. State Board of Administration of Florida Retirement System now owns 8,430 shares of the company’s stock valued at $409,000 after buying an additional 1,560 shares during the last quarter. Pzena Investment Management LLC boosted its stake in USANA Health Sciences by 3.1% in the first quarter. Pzena Investment Management LLC now owns 785,344 shares of the company’s stock valued at $38,089,000 after acquiring an additional 23,729 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in USANA Health Sciences by 18.1% in the first quarter. BNP Paribas Financial Markets now owns 38,820 shares of the company’s stock worth $1,883,000 after purchasing an additional 5,952 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of USANA Health Sciences by 58.9% during the first quarter. Assenagon Asset Management S.A. now owns 82,199 shares of the company’s stock worth $3,987,000 after purchasing an additional 30,485 shares in the last quarter. Finally, DGS Capital Management LLC lifted its holdings in shares of USANA Health Sciences by 61.8% during the 1st quarter. DGS Capital Management LLC now owns 7,258 shares of the company’s stock valued at $352,000 after purchasing an additional 2,773 shares during the last quarter. Institutional investors own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.